Bad Miss For Biocon’s Bevacizumab In US But Firm In 'Good Place'
Indian Company Remains Upbeat As It Reports Full-Year Results
Biocon is still awaiting a site inspection as pandemic-related delays keep its Viatris-partnered bevacizumab out of the US market, though the Indian company believes it can still make good and garner market share. All eyes are also on traction for its insulin glargine via increased share of formulary contracts.
